Full Press Release Details
Fourth Quarter and Year End 2018 Financial Results
2018 HIGHLIGHTS compared to 2017:
San Jose, Cal. - February
27, 2019 - Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that
provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported
financial results for the three months and year ended December 31, 2018.
"When disease processes are
recognized earlier, preventive healthcare can be started sooner, thus providing a cost-efficient, practical means to achieve better
patient management," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "We believe that
our QuantaFlo product allows our customers to help those under their care in just such a manner, which we believe is a
contributing factor to our company's continued growth."
For the year ended December 31,
2018, compared to 2017, Semler Scientific reported:
During the year of 2018, total liabilities
decreased by $3,298,000 and all principal and accrued interest on notes were retired.
For the three months ended December
31, 2018, compared to the corresponding period of 2017, Semler Scientific reported:
2018 MAJOR ACCOMPLISHMENTS
Among the accomplishments recognized
in the year of 2018 were:
In 2019, Semler Scientific expects
continued profitability and generation of cash from operating activities. It is the company's intent to grow revenues at
a faster rate than expenses and to remain profitable.
"Our objectives are to work
with the healthcare industry to reduce avoidable healthcare costs and improve health outcomes of patients," said Dr. Murphy-Chutorian.
"We believe our customers have incorporated our product into their healthcare systems and are achieving the intended clinical
benefits and improved medical economics."
Notice of Conference Call
Semler Scientific will host a conference
call at 11 a.m. ET, February, 27, 2019. The call will address results of the fourth quarter and year-end 2018 as well as provide
a business update on the company's market outlook and strategies for the near-term future.
The conference call may be accessed
by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you
would like to join the "Semler Scientific Fourth Quarter and Year-to-Date 2018 Financial Results Call, conference ID#: 3068129."
The conference call will be archived on Semler's website at www.semlerscientific.com.
of U.S. Dollars, except for share and per share data)
| For the three months ended December 31, | For the year ended December 31, | |||||||||||||||
| (Unaudited) | (Unaudited) | (Audited) | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenues | $ | 5,964 | $ | 4,213 | $ | 21,491 | $ | 12,452 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenues | 704 | 698 | 2,703 | 2,553 | ||||||||||||
| Engineering and product development | 643 | 486 | 2,085 | 1,831 | ||||||||||||
| Sales and marketing | 1,919 | 1,575 | 7,202 | 5,078 | ||||||||||||
| General and administrative | 1,251 | 1,078 | 4,159 | 3,843 | ||||||||||||
| Total operating expenses | 4,517 | 3,837 | 16,149 | 13,305 | ||||||||||||
| Income (loss) from operations | 1,447 | 376 | 5,342 | (853 | ) | |||||||||||
| Interest income (expense) | 1 | (42 | ) | (59 | ) | (231 | ) | |||||||||
| Interest expense -- related parties | (35 | ) | (75 | ) | (239 | ) | (233 | ) | ||||||||
| Loss on extinguishment of loans | - | - | - | (179 | ) | |||||||||||
| Other expense | - | (5 | ) | (4 | ) | (5 | ) | |||||||||
| Other expense | (34 | ) | (122 | ) | (302 | ) | (648 | ) | ||||||||
| Pre-tax net income (loss) | $ | 1,413 | $ | 254 | $ | 5,040 | $ | (1,501 | ) | |||||||
| Provision for income taxes | (26 | ) | - | (26 | ) | (9 | ) | |||||||||
| Net income (loss) | 1,387 | 254 | 5,014 | (1,510 | ) | |||||||||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | $ | 0.22 | $ | 0.05 | $ | 0.82 | $ | (0.28 | ) | |||||||
| Diluted | $ | 0.17 | $ | 0.04 | $ | 0.66 | $ | (0.28 | ) | |||||||
| Weighted average number of shares used in | ||||||||||||||||
| computing earnings (loss) per share: | ||||||||||||||||
| Basic | 6,320,003 | 5,581,727 | 6,079,326 | 5,405,388 | ||||||||||||
| Diluted | 8,120,453 | 6,652,861 | 7,629,523 | 5,405,388 |
Semler Scientific, Inc.
Condensed Balance Sheets
(In thousands of U.S. Dollars)
| At December 31, | ||||||||
| 2018 | 2017 | |||||||
| Cash | $ | 3,284 | $ | 1,457 | ||||
| Other current assets | 2,954 | 1,426 | ||||||
| Noncurrent assets | 1,481 | 1,355 | ||||||
| Total assets | $ | 7,719 | $ | 4,238 | ||||
| Current liabilities | 3,512 | 5,140 | ||||||
| Noncurrent liabilities | 11 | 1,681 | ||||||
| Stockholders' equity (deficit) | 4,196 | (2,583 | ) | |||||
| Total liabilities and stockholders' equity (deficit) | $ | 7,719 | $ | 4,238 |
About Semler Scientific,
Semler Scientific, Inc. is an
emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare
providers. Semler Scientific's mission is to develop, manufacture and market innovative proprietary products and services
that assist its customers in evaluating and treating chronic diseases. Semler Scientific's first patented and U.S.
Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities
to aid in the diagnosis of peripheral arterial disease. In March 2015, Semler Scientific received FDA 510(k) clearance for the
next generation version of this product named QuantaFlo , which was commercially launched in August 2015 to more comprehensively
evaluate our customers' patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide
valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care.
Additional information about Semler can be found at semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking"
statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may,"
"will," "expect," "anticipate," "estimate," "project," "would,"
"could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions.
The forward-looking statements in this release include statements regarding continued profitability and cash generated from operations,
as well as the ability to grow revenues faster than expenses. Such forward-looking statements are subject to a number of risks
and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such
as whether or not insurance plans and other customers will continue to license its cardiovascular testing products, and its ability
to continue to control expenses, along with those statements detailed in Semler Scientific's SEC filings. These forward-looking
statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs.
There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially
from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their
entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of
the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required
S.A. Noonan Communications
SOURCE: Semler Scientific,